We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+35.58%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
+$29.9M
Cap. Flow
-$3.38M
Cap. Flow %
-2.55%
Top 10 Hldgs %
99.02%
Holding
13
New
–
Increased
5
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$599K
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$598K
3
OVID icon
Ovid Therapeutics
OVID
+$368K
4
COGT icon
Cogent Biosciences
COGT
+$153K
5
KZR
Kezar Life Sciences
KZR
+$19K

Top Sells

Rank Stock Value
1
DTIL icon
Precision BioSciences
DTIL
+$2.11M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$983K
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$756K
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$474K
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$386K

Sector Composition

Rank Sector Weight
1 Healthcare 50.16%
2 Communication Services 49.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LVGO
1
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$66.1M 49.84%
2,636,640
– –
ORTX
2
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$40.7M 30.68%
295,849
-3,172
-1% -$386K
DTIL icon
3
Precision BioSciences
DTIL
$232M
$12.3M 9.24%
29,412
-6,714
-19% -$2.11M
OVID icon
4
Ovid Therapeutics
OVID
$572M
$3.5M 2.64%
843,931
+116,671
+16% +$368K
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$2.08M 1.57%
26,000
+8,000
+44% +$599K
CRVS icon
6
Corvus Pharmaceuticals
CRVS
$1.24B
$2.01M 1.52%
370,307
-20,000
-5% -$70K
RARE icon
7
Ultragenyx Pharmaceutical
RARE
$2.59B
$1.64M 1.24%
38,500
+14,500
+60% +$598K
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.59M 1.2%
20,000
-8,000
-29% -$474K
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$729K 0.55%
10,000
-12,464
-55% -$756K
BLUE
10
DELISTED
bluebird bio
BLUE
$702K 0.53%
618
-308
-33% -$335K
COGT icon
11
Cogent Biosciences
COGT
$6.44B
$678K 0.51%
235,201
+37,500
+19% +$153K
KZR
12
DELISTED
Kezar Life Sciences
KZR
$619K 0.47%
15,426
+617
+4% +$19K
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-35,000
Closed -$983K

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, CHI Advisors held 13 positions worth $133M, up 29% from $103M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

CHI Advisors's Q4 2019 filing shows 5 increased, 6 reduced and 1 closed positions. The largest sale was Precision BioSciences, an estimated $2.11M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 55% a quarter earlier, followed by Communication Services.

  • CHI Advisors added most to Blueprint Medicines in Q4 2019, an estimated $599K increase.
  • CHI Advisors's biggest Q4 2019 reduction was Precision BioSciences, cutting an estimated $2.11M.
  • CHI Advisors fully exited Audentes Therapeutics, Inc in Q4 2019, selling an estimated $983K.
  • CHI Advisors's ten largest holdings make up 99% of its $133M portfolio in Q4 2019.
  • CHI Advisors opened 0 new positions and closed 1 in Q4 2019.
  • CHI Advisors's portfolio value rose 29% quarter-over-quarter to $133M.

Based on CHI Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.